(Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved memantine ... and Everolimus 2 mg, 3 mg and 5 mg extended-release ...

Furthermore, the new formulation of memantine delivers a higher dose of memantine, providing a total of 28 mg instead of 20 mg daily. As a next step in determining the overall benefit brought by ...

(mean 6.3); 82 patients were randomized to memantine (10 mg/day) and 84 were randomized to placebo. Overall outcomes significantly favored the treatment group on measures of global assessment and ...